Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc develops and manufactures therapeutic medical devices and healthcare technology for chronic diseases and procedural care. Its news commonly covers regulatory clearances and CE marks, product launches, clinical data, acquisitions, and financial results across cardiovascular, cardiac rhythm management, cranial and spinal technologies, surgical navigation, robotics, and ablation systems.
Recent company updates include the Stealth AXiS™ surgical system for planning, navigation, and robotics; the Affera™ mapping and ablation system with Sphere-9™ and Sphere-360™ catheters; the OmniaSecure™ defibrillation lead; and the completed CathWorks acquisition, including the FFRangio® System for coronary artery disease assessment.
Medtronic (NYSE: MDT) presented significant clinical trial results at the 2020 SCAI Scientific Sessions. The 10-year outcomes for the Melody™ Transcatheter Pulmonary Valve (TPV) showed robust long-term safety and effectiveness, with 97% of patients experiencing minimal pulmonary regurgitation. Additionally, the investigational Harmony™ TPV trial successfully met its primary endpoints at six months, with 89% of participants achieving acceptable hemodynamic function. These results underscore Medtronic's commitment to improving therapies for congenital heart disease patients.
Medtronic (NYSE:MDT) announced the FDA approval of its Cobalt and Crome implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds) featuring advanced remote monitoring via the MyCareLink Heart™ mobile app. Clinical trials presented during the virtual Heart Rhythm Society Scientific Sessions showed that patients using this app had a 94.6% adherence rate in monitoring, outperforming traditional methods. The Micra pacemaker showed a 66% reduction in complications, indicating its effectiveness in real-world settings.
Medtronic plc (NYSE: MDT) will report its financial results for Q4 and full fiscal year 2020 on May 21, 2020, at approximately 5:45 a.m. CDT. A webcast discussion is scheduled for 7:00 a.m. CDT the same day. Financial results will cover the period ending April 24, 2020. Medtronic also plans to report its fiscal year 2021 results on August 25, November 24, February 23, and May 27 of 2021. The company's Institutional Investor & Analyst Day has been postponed due to the COVID-19 pandemic. More details will be announced closer to the specific event dates.
Medtronic has expanded its Medtronic Assurance program to support U.S. diabetes customers who have lost their health insurance due to COVID-19-related job loss. Eligible customers can receive a 3-month supply of glucose sensors and insulin pump supplies at no cost. This initiative includes flexible payment plans and financial assistance for those significantly impacted by healthcare costs. The company aims to ensure continued access to diabetes technology during these challenging times.
Summary not available.